Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C64618
http://purl.obolibrary.org/obo/NCIT_C64618
|
|---|---|
| Preferred Name | Silatecan AR-67 |
| Definitions |
A synthetic, highly lipophilic derivative of camptothecin, with potential antineoplastic and radiosensitizing activities. 7-tert-butyldimethylsilyl-10-hydroxycamptothecin binds to and stabilizes the topoisomerase I-DNA covalent complex. This inhibits the religation of topoisomerase I-mediated single-stranded DNA breaks and produces lethal double-stranded DNA breaks when encountered by the DNA replication machinery, thereby inhibiting DNA replication and inducing apoptosis. Camptothecin readily undergoes hydrolysis at physiological pH, changing its conformation from the active lactone structure to an inactive carboxylate form. Modifications on the E ring of camptothecin prevent binding of human serum albumin, which prefers the inactive carboxylate form, thereby enhancing the stability of the active lactone structure and resulting in prolonged agent activity. In addition, this agent sensitizes tumor cells toward radiation treatment.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A synthetic, highly lipophilic derivative of camptothecin, with potential antineoplastic and radiosensitizing activities. 7-tert-butyldimethylsilyl-10-hydroxycamptothecin binds to and stabilizes the topoisomerase I-DNA covalent complex. This inhibits the religation of topoisomerase I-mediated single-stranded DNA breaks and produces lethal double-stranded DNA breaks when encountered by the DNA replication machinery, thereby inhibiting DNA replication and inducing apoptosis. Camptothecin readily undergoes hydrolysis at physiological pH, changing its conformation from the active lactone structure to an inactive carboxylate form. Modifications on the E ring of camptothecin prevent binding of human serum albumin, which prefers the inactive carboxylate form, thereby enhancing the stability of the active lactone structure and resulting in prolonged agent activity. In addition, this agent sensitizes tumor cells toward radiation treatment. |
|---|---|
| prefLabel | Silatecan AR-67
|
| label | Silatecan AR-67
|
| PDQ_Closed_Trial_Search_ID | 522726
|
| code | C64618
|
| Has_Target | |
| prefixIRI | NCIT:C64618
|
| in_subset |
See more
See less
|
| Display_Name | Silatecan AR-67
|
| Preferred_Name | Silatecan AR-67
|
| FDA_UNII_Code | 3YEA04NV6H
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Silatecan AR-67
|
| CAS_Registry | 220913-32-6
|
| NCI_Drug_Dictionary_ID | 522726
|
| Legacy Concept Name | _7-Tert-butyldimethylsilyl-10-hydroxycamptothecin
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 522726
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C1955483
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |